Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this recognition.
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
Anti-integrin αvβ6 antibodies are detected in about 90% of UC patients, and the results of basic research suggest that these autoantibodies themselves may be causing the disease
JSR Life Sciences announced that its lead product, Amsphere™ A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment
This project will conduct R&D aimed at the establishment and practical application of a wide range of fundamental technologies related to intestinal microbiome drug discovery for the creation of in...
MBL donated 20,000 their SARS-CoV-2 antigen test kits "GLINE-2019-nCoV Ag kit" to Ina City, Nagano Prefecture, where their research and production facilities are located
The kit is designed to detect the presence or absence of AZF deletion and the type of AZF deletion in Japanese men prior to microdissection testicular sperm extraction for male infertility
6 of 23
Receive JSR Life Sciences news on your RSS reader.
